drugset / Trial / NCT07170787
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, dose-escalation and cohort expansion study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant protein) combine with IMM01(Anti-CD47 Recombinant Protein) in patients with advanced solid tumors who have received at least first line treatment in past.
Timeline
- Start
- 2025-10-15
- Primary completion
- 2029-02
- Completion
- 2029-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM01 | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | IMM01 | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Subject | IMM01 | Protein / enzyme biologic | 3 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 10 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 20 mg/kg | Intravenous |